九味肝泰胶囊联合恩替卡韦治疗慢性乙型肝炎临床研究

摘要

Objective:To observe the clinical effect and mechanism of entecavir combined with Jiuwei Gantai capsule in treatment of chronic hepatitis B.Methods:Eighty-two patients with chronic hepatitis B were randomly divided into 2 groups:the control group (40cases) was only given entecavir 0.5mg/d by oral use.The treatment course (42cases) was above one year.The treatment group was added with Jiuwei Gantai capsule for 24 weeks on the basis of treatment with entecavir 0.5mg/d,then only given entecavir.The treatment course was also one year.The changes of clinical symptons,liver function and HBV DNA,indexes of hepatic fibrosis were observed after 24 weeks'treatment in both groups.Results:Compared with the control group,clinical symptoms,liver function and serum hepatic fibrosis indexes were improved more in the treatment group (P ＜ 0.05),but there was no significant difference in the negative conversation rate of HBV DNA between the both groups (P ＞ 0.05).Conclusion:Jiuwei Gantai capsule combined with entecavir has a significant recent effect on chronic hepatitis B,its mechanism may be relevant to improve liver function,inhibit the liver fibrosis.%目的:观察九味肝泰胶囊联合恩替卡韦治疗慢性乙型肝炎的临床疗效及探讨其机制.方法:将82例慢性乙型肝炎患者按随机对照原则分为两组:对照组患者(40例)口服恩替卡韦0.5mg/d,疗程1年以上；治疗组患者(42例)口服恩替卡韦0.5mg/d,加服九味肝泰胶囊,治疗24周,然后单服恩替卡韦,疗程1年以上.观察两组患者治疗1年时临床症状、肝功能、HBV DNA、肝纤维化指标的改变情况.结果:治疗24周后,治疗组患者临床症状、肝功能、血清肝纤维化指标与对照组比较改善显著(P＜0.05).但两组在HBV DNA转阴方面比较差异无显著性意义,(P＞0.05).结论:九味肝泰胶囊联合恩替卡韦治疗慢性乙型肝炎近期疗效显著,其作用机制与改善肝功能、抑制肝脏纤维化有关.